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OBJECTIVE— Latent autoimmune diabetes in adults is type 1 diabetes presenting as non–
insulin dependent diabetes. One feature of the selection criteria is time independent of insulin
treatment. We examine the validity of this criterion.
RESEARCH DESIGN AND METHODS— Patients were recruited in nine European
centers, and clinicians reported on criteria for initiating insulin. All patients were tested for GAD
antibodies (GADAs) in a central laboratory. We examined time to insulin treatment for GADA-
positive patients in six participating centers.
RESULTS— There was intercenter variation in the criteria used to initiate insulin. Median
time to insulin was 16.15 months (interqartile range 6.7–25.5) in centers with GADA testing
compared with 45.6 months (29.5–61.8) in centers without routine GADA testing (P 0.002).
CONCLUSION— Time to insulin should not be used to define patients with LADA because
it is dependent on local clinical judgment and the use of laboratory tests for GADA.
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L atent autoimmune diabetes in adults(LADA) is a term applied to patientswith apparent type 2 diabetes but
who have pancreatic islet cell auto-
antibodies. LADA patients have features
of type 1 diabetes, including genetic risk
markers and reduced rates of the meta-
bolic syndrome (1–3). However, the se-
lection criteria used in LADA research
varies greatly (4–13). While time from di-
agnosis to insulin treatment is not in-
cluded in some definitions, others require
freedom from insulin treatment for a vari-
able period ranging from 3 to 12 months.
In this study, we examine the validity of
using time to insulin treatment as part of a
definition of LADA.
RESEARCH DESIGN AND
METHODS— Nine centers recruited
patients (aged 30–69 with primary dia-
betes, diagnosed within the past 5 years).
GAD antibody (GADA) tests were per-
formed in St. Bartholomew’s Hospital and
in the London Hospital using a Diabetes
Antibody Standardization Programme
(DASP) validated assay (in the 2005 DASP
antibody workshop, the assay had a sen-
sitivity 72% and specificity 95%). Values
70 World Health Organization units
were regarded as positive. All patients
were assayed in duplicate and included an
in-house positive and negative control
subject.
Clinicians in all nine centers com-
pleted a questionnaire reporting the crite-
ria for initiating insulin in their center.
One questionnaire per center reported
the consensus opinion of the clinicians in
that center. Center size varied between
two and seven clinicians. The medical
notes of the GAD-positive patients (522 of
5,812) were analyzed to examine time to
insulin. Three centers were excluded
from the analysis because these data were
not in a format that could be analyzed.
Cox regression/Kaplan-Meier analysis
were used to examine survival in terms of
time to insulin in GAD-positive patients
in centers performing routine GADA test-
ing compared with those not testing for
GADA.
RESULTS— The criteria for initiating
insulin varied between centers. All used
A1C and weight loss, eight of nine con-
sidered ketones, seven of nine considered
complications, six of nine considered pa-
tient preference and/or other treatments,
and five of nine used age and/or C-
peptide. All the centers except two in the
U.K. used GADA testing.
In centers where GADA testing was
performed, the median time to insulin
treatment for those testing GADA positive
in the central laboratory was earlier com-
pared with that for centers with no GAD
testing (Fig. 1). For GAD testing centers
(Odense, n  32; Barcelona, n  67; Vi-
enna, n  35; and Lyon, n  68), the
median time was 4.8 (interquartile range
0 –12.8), 9.4 (1.1–17.8), 31 (3.5–59),
and 29.4 (17.6 – 41) months, respec-
tively, compared with that of non–GADA
testing areas (Belfast, n  66; London,
n  50) where median time (months) to
insulin treatment was 38.1 (20.5–55.6)
and 47 (29.5– 64.8) months (P 
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0.0001). Therefore, if a definition of
LADA stated that a person should be in-
dependent of insulin for 6 months
(1,7,11), estimates of prevalence would
be low in Denmark, Austria, France, and
Spain but high in Belfast and London.
CONCLUSIONS— Time to insulin
treatment is dependent on local clinical
judgement and not on the disease pro-
cess. Since that judgement is based on the
presence of GADA, it follows that to de-
fine LADA on GADA positivity and the
lack of initial need for insulin treatment is
fraught with difficulties since the one of-
ten precludes the other.
The term latent, when applied to
LADA, refers to the latency of autoimmu-
nity, which is only revealed by testing for
autoantibodies. The widespread clinical
use of GADA testing on the continent but
not in the U.K. means that the presence of
a diabetes-associated autoantibody is no
longer latent in many European centers.
The level of GADA titer influences pro-
gression to insulin therapy. In the UK Pro-
spective Diabetes Study 71 (14), the risk
of requiring insulin in patients with
GADA levels of 20–37.4 units was 20%,
but GADA levels of 37.5–101 units give a
50 –75% risk. These findings are sup-
ported by Buzzetti et al. (15), who found
a bimodal distribution of GADA titers. It
is important to note that there is large
variation between laboratories with re-
spect to GADA levels defining an abnor-
mality, and caution should be exercised in
using defined units; for our study, a cutoff
of 70 World Health Organization units
was used. Therefore, to accurately iden-
tify patients with LADA, perhaps a mini-
mum level of GAD units should be
selected within a definition (16).
Another feature of LADA not consid-
ered here is the presence of ketonuria. Ke-
tonuria is a feature of classical type 1
diabetes but can also occur in type 2 dia-
betes. Some patients, from certain ethnic
groups, can present with ketoacidosis but
subsequently come off insulin treatment,
and some may have GADA. In LADA pa-
tients, neither ketonuria nor ketoacidosis
is present at diagnosis, and in this way
LADA is distinct from ketosis prone di-
abetes, though the distinction may in
some cases be more apparent than real
(17). To separate LADA from classical
type 1 diabetes, we may need to use some
defined level of ketonuria or ketonaemia
at diagnosis.
A further criteria used in the diagno-
sis of LADA is age. However, patients with
GADA can present with non–insulin re-
quiring diabetes in childhood (17,18). In
our opinion, criteria to define LADA
could include the presence of diabetes-
associated autoantibodies, without keto-
acidosis at diagnosis and irrespective of
time independent of insulin treatment.
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